Richardson Ryan 4

What Happened

• Ryan Richardson, a director of Autolus Therapeutics plc (AUTL), received two restricted stock unit (RSU) awards on June 29, 2026 totaling 79,167 RSUs (31,667 + 47,500). The awards were granted at $0.00 (derivative awards), so no cash was exchanged at grant. The filing was submitted on July 1, 2026.

Key Details

• Transaction date: 2026-06-29; Form 4 filed: 2026-07-01 (timely).
• Grant amounts and price: 31,667 RSUs @ $0.00 and 47,500 RSUs @ $0.00 (total 79,167 RSUs).
• Reported value on Form 4: $0 (derivative awards; actual value depends on Autolus ADS price at settlement/vesting).
• Shares owned after transaction: not stated in the provided excerpt of the filing.
• Relevant footnotes from the filing:
  • F1: Each RSU represents a contingent right to one American Depositary Share (ADS). Each ADS is convertible into one ordinary share at the reporting person’s option.
  • F2: The RSUs vest in one installment on June 29, 2027.
  • F3: (Related note) Share options (separate from these RSUs) vest in twelve equal monthly installments commencing July 29, 2026.
• Filing timeliness: The Form 4 was filed within the typical two-business-day window following the grant.

Context

• These RSUs are compensation awards (not an open-market purchase or sale). They grant the right to receive ADSs in the future if vesting conditions are met; they do not reflect an immediate cash investment by the insider.
• The reported grant value is shown as $0 on the Form 4 because RSUs are granted without cash consideration; their future worth will depend on Autolus’s ADS price at vesting/settlement.